Federal: concentrated 7-OH
DEA published a July 6, 2026 notice of intent to temporarily place 7-OH above specified thresholds into Schedule I. Proposed coverage includes botanical material above 0.050% 7-OH by dry weight, and synthetic/processed articles above 0.050% concentration or 1.00 mg per article. Ordinary botanical kratom below the threshold is stated as outside this temporary action’s target—the threshold is regulatory, not a claim that pharmacology changes below it.
Federal: MP, MGM-15, MGM-16
A separate July 6, 2026 notice of intent targets mitragynine pseudoindoxyl, MGM-15, and MGM-16 by name. As with 7-OH, a final temporary order must be located before claiming Schedule I status.
FDA position
FDA states concentrated or enhanced 7-OH products are not approved drugs, lawful dietary ingredients, or authorized food additives, and has recommended scheduling and taken enforcement/seizure actions. Public messaging distinguishes concentrated products from natural leaf while warning about MP and related analogues.
Selected state actions (snapshot)
| Jurisdiction | Verified development | Clinical relevance |
|---|---|---|
| California | CDPH: kratom- and 7-OH-containing foods/supplements/unapproved drugs illegal to manufacture or sell for consumption; active enforcement/seizures. Food/drug enforcement ≠ blanket Schedule I listing. | Retail access can contract before federal scheduling. |
| Connecticut | Guidance reports Schedule I placement of kratom and 7-OH (verify current schedule). | State criminal exposure may already differ from federal status. |
| Florida | Emergency Rule 2ER26-1 (effective as verified July 1, 2026) places specified 7-OH-related compounds into Schedule I under rule terms. | State exposure while federal temporary orders remain pending. |
| New York | S8925A passed both chambers (June 2026); not shown enacted on bill page at last check—retail threshold proposal. | Civil retail prohibition ≠ Schedule I. |
| Texas | Public-health advisory on kratom and concentrated 7-OH. | Supports screening and education; not itself scheduling. |
Public-health signal
America’s Poison Centers reported 593 7-OH exposure reports in 2025 and 901 in January–June 2026. Among 7-OH-only reports, 38.8% were classified serious, 63.8% treated at a healthcare facility, and 20.5% hospitalized. Surveillance is not incidence—but the direction of travel is clear.
Treatment-capacity concern
Pairing regulation with clinician alerts, naloxone, rapid buprenorphine/methadone access, and surveillance for fentanyl substitution is the public-health point of this resource. See treatment and evidence.